Molecules belonging to the class of nonsteroidal anti-inflammatory drugs (NSAIDs) that inhibit COX2 enzyme, which is involved in inflammation and pain processes. It was found that this enzyme is also involved in the growth of cancer cells. The FDA has approved a drug called “Celebrex” for FAP, a condition that raises the risk of colorectal cancer (see family polyposis).
Facebook
Twitter
LinkedIn
WhatsApp
COX-2 Inhibitors
To check if our service suits your case
We need to talk
Improve therapeutic outcomes, prolong life and quality of life, are our main business.
We support access to and expand cancer treatments beyond the standard of care, with the most advanced and innovative treatment options in the world, personally matching the individual cancer patient’s medical condition and with the support of top tier oncologists.
Article categories
קטגוריות המאמרים
Popular topics
Tags
Advanced Breast Cancer
Advanced Cancer Treatment
ASCO 2025
ASCO 2026
Biological Drugs
Breast Cancer
Cancer Research
CAR T treatments
centralny układ nerwowy
Chemotherapy
Clinical Trial Enrollment
Clinical Trials
Fulvestrant
Gedatolisib
Genetic Engineering Treatments
Genomic Testing
HER3-DXd
Hormone Receptor Positive Breast Cancer
HPV-negative HNSCC
HR Positive Breast Cancer
Immunotherapy
innowacyjne terapie onkologiczne
Keytruda
leczenie LMD
Medical Cannabis
Metastatic Pancreatic Cancer
MTAP Loss
Novel Cancer Therapies
nowe leczenie raka
nowotwór piersi
Oncology
Pancreatic Cancer
Precision Oncology
przerzuty do opon mózgowo-rdzeniowych
Recurrent Head and Neck Cancer
Revolution Medicines
Rybrevant
Rybrevant FASPRO
Stage 4 Cancer
Tango Therapeutics
Targeted Drugs
Targeted Therapy
Trial-In Pharma
VIKTORIA-1
Vopimetostat
